本帖最后由 老马 于 2012-1-13 21:20 编辑
+ h/ P3 y$ @" K' Q; r, }5 \5 r: s" ]9 E: W; L% a
爱必妥和阿瓦斯丁的比较
0 G! B4 M8 y. N. o+ o
0 w v; g' |5 \3 Y; i! K- a
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 ]7 \* P& e$ ~7 T9 e; z0 Y
0 {' P- g. A* Z, H! X; @8 [
" H- x6 Y" ^) u. e: p0 Ahttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/! [; a6 g9 j5 |0 w( U- t
==================================================8 N/ I/ o1 U+ a. v; p
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 e% ?0 ~0 I4 e- r6 ?$ YPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
$ F, X% K$ I4 @Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.' z- w% A6 w4 L* x; l! l) e
|